HC Wainwright & Co. Downgrades Heron Therapeutics to Neutral
HC Wainwright & Co. analyst Brandon Folkes downgrades Heron Therapeutics (NASDAQ:HRTX) from Buy to Neutral.
Read original at benzingaStocks · News reference
8-K filing — HERON THERAPEUTICS, INC. /DE/ (HRTX)
Filed: 2026-08-14 AccNo: 0001193125-26-352403 Size: 231 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.03: Material Modifications to Rights of Security Holders Item 9.01: Financial Statements and Exhibits
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Aug 14, 2026, 8:30 PM
- Checked
- Aug 14, 2026, 8:30 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Heron Therapeutics shares are trading lower after the company reported worse-than-expected Q2 financial results.
Read original at benzingaHeron Therapeutics Q2 EPS $(0.03) Misses $(0.01) Estimate, Sales $37.666M Miss $42.200M Estimate
Heron Therapeutics (NASDAQ:HRTX) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.01) by Infinity percent. This is a 50 percent decrease over losses of $(0.02) per share
Read original at benzinga